AR076344A1 - Metodo de terapia complementaria contra el cancer - Google Patents
Metodo de terapia complementaria contra el cancerInfo
- Publication number
- AR076344A1 AR076344A1 ARP100101306A ARP100101306A AR076344A1 AR 076344 A1 AR076344 A1 AR 076344A1 AR P100101306 A ARP100101306 A AR P100101306A AR P100101306 A ARP100101306 A AR P100101306A AR 076344 A1 AR076344 A1 AR 076344A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- vegf
- patient
- specific
- antagonist
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000000295 complement effect Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 3
- 230000004083 survival effect Effects 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229960000397 bevacizumab Drugs 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Fertilizers (AREA)
Abstract
Reivindicacion 1: Un método de terapia complementaria, que comprende la administracion a un paciente con cáncer, luego de la cirugía definitiva, de una cantidad eficaz de un antagonista específico de VEGF, de manera de extender la sobrevida libre de enfermedad (DFS) o la sobrevida general (OS) en el paciente, donde el antagonista específico de VEGF se administra durante más de un ano. Reivindicacion 26: El método de cualquiera de las reivindicaciones 1-24, donde el método además comprende la administracion de un agente quimioterapéutico al paciente. Reivindicacion 28: El método de cualquiera de las reivindicaciones 1-24, donde el antagonista específico de VEGF es un anticuerpo anti-VEGF. Reivindicacion 30: El método de la reivindicacion 28, donde el anticuerpo anti-VEGF es bevacizumab. Reivindicacion 31: El método de la reivindicacion 30, donde el anticuerpo anti-VEGF se une al mismo epítopo que el anticuerpo monoclonal anti-VEGF A4.6.1 producido por el hibridoma ATCC HB 10709. Reivindicacion 33: El método de cualquiera de las reivindicaciones 1-32, donde el cáncer es cáncer colorrectal, cáncer de mama, cáncer de pulmon, cáncer renal, cáncer gástrico, cáncer de ovario o glioblastoma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17100809P | 2009-04-20 | 2009-04-20 | |
| US17131809P | 2009-04-21 | 2009-04-21 | |
| US18119509P | 2009-05-26 | 2009-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076344A1 true AR076344A1 (es) | 2011-06-01 |
Family
ID=42235124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101306A AR076344A1 (es) | 2009-04-20 | 2010-04-20 | Metodo de terapia complementaria contra el cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100266589A1 (es) |
| EP (1) | EP2421558A1 (es) |
| JP (1) | JP2012524083A (es) |
| KR (1) | KR20120096401A (es) |
| CN (1) | CN102458467A (es) |
| AR (1) | AR076344A1 (es) |
| AU (1) | AU2010239368A1 (es) |
| BR (1) | BRPI1006438A2 (es) |
| CA (1) | CA2759030A1 (es) |
| CL (1) | CL2011002610A1 (es) |
| CO (1) | CO6450651A2 (es) |
| CR (1) | CR20110553A (es) |
| IL (1) | IL215764A0 (es) |
| MA (1) | MA33323B1 (es) |
| MX (1) | MX2011010955A (es) |
| RU (1) | RU2011147051A (es) |
| SG (1) | SG175289A1 (es) |
| TW (1) | TW201106969A (es) |
| WO (1) | WO2010123891A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750124B2 (en) * | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| US11536713B2 (en) | 2009-12-25 | 2022-12-27 | Chugai Seiyaku Kabushiki Kaisha | Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein |
| US20120087915A1 (en) | 2010-06-03 | 2012-04-12 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| JP6230789B2 (ja) | 2010-10-06 | 2017-11-15 | 中外製薬株式会社 | 癌幹細胞集団及びその作製方法 |
| JP6077997B2 (ja) | 2011-09-07 | 2017-02-08 | 中外製薬株式会社 | 癌幹細胞の分離 |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| JP6291254B2 (ja) | 2011-10-28 | 2018-03-14 | 中外製薬株式会社 | 癌幹細胞特異的分子 |
| MY186099A (en) * | 2012-05-31 | 2021-06-22 | Genentech Inc | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
| WO2014025813A1 (en) * | 2012-08-07 | 2014-02-13 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| AU2013337663A1 (en) | 2012-11-02 | 2015-06-11 | Pharmacyclics Llc | TEC family kinase inhibitor adjuvant therapy |
| US20140348821A1 (en) * | 2013-05-24 | 2014-11-27 | Nsabp Foundation, Inc. | Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| JP2017523776A (ja) | 2014-07-14 | 2017-08-24 | ジェネンテック， インコーポレイテッド | 膠芽腫の診断方法及びその治療用組成物 |
| EP3212233B1 (en) | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| WO2017042318A1 (en) * | 2015-09-10 | 2017-03-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chemerin polypeptide for the treatment of cancer-induced cachexia |
| AU2016326609B2 (en) | 2015-09-23 | 2023-03-09 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5730977A (en) * | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP3957765B2 (ja) * | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| WO2005000900A1 (en) * | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Treatment with anti-vegf antibodies |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7758859B2 (en) * | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| US20060009360A1 (en) * | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| HUE029445T2 (en) * | 2006-12-19 | 2017-02-28 | Genentech Inc | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors |
| CN101646458A (zh) * | 2007-02-01 | 2010-02-10 | 健泰科生物技术公司 | 使用血管发生抑制剂的联合疗法 |
| TWI468417B (zh) * | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
-
2010
- 2010-04-20 MX MX2011010955A patent/MX2011010955A/es not_active Application Discontinuation
- 2010-04-20 CA CA2759030A patent/CA2759030A1/en not_active Abandoned
- 2010-04-20 RU RU2011147051/15A patent/RU2011147051A/ru not_active Application Discontinuation
- 2010-04-20 CN CN2010800273827A patent/CN102458467A/zh active Pending
- 2010-04-20 SG SG2011076940A patent/SG175289A1/en unknown
- 2010-04-20 AU AU2010239368A patent/AU2010239368A1/en not_active Abandoned
- 2010-04-20 TW TW099112369A patent/TW201106969A/zh unknown
- 2010-04-20 AR ARP100101306A patent/AR076344A1/es unknown
- 2010-04-20 JP JP2012506004A patent/JP2012524083A/ja active Pending
- 2010-04-20 EP EP10714820A patent/EP2421558A1/en not_active Withdrawn
- 2010-04-20 BR BRPI1006438A patent/BRPI1006438A2/pt not_active IP Right Cessation
- 2010-04-20 US US12/763,704 patent/US20100266589A1/en not_active Abandoned
- 2010-04-20 KR KR1020117027566A patent/KR20120096401A/ko not_active Withdrawn
- 2010-04-20 MA MA34342A patent/MA33323B1/fr unknown
- 2010-04-20 WO PCT/US2010/031740 patent/WO2010123891A1/en not_active Ceased
-
2011
- 2011-10-19 CL CL2011002610A patent/CL2011002610A1/es unknown
- 2011-10-19 CR CR20110553A patent/CR20110553A/es unknown
- 2011-10-23 IL IL215764A patent/IL215764A0/en unknown
- 2011-10-24 CO CO11143266A patent/CO6450651A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2011002610A1 (es) | 2012-04-09 |
| CA2759030A1 (en) | 2010-10-28 |
| EP2421558A1 (en) | 2012-02-29 |
| AU2010239368A1 (en) | 2011-11-10 |
| RU2011147051A (ru) | 2013-05-27 |
| CO6450651A2 (es) | 2012-05-31 |
| BRPI1006438A2 (pt) | 2016-09-27 |
| US20100266589A1 (en) | 2010-10-21 |
| IL215764A0 (en) | 2012-01-31 |
| MA33323B1 (fr) | 2012-06-01 |
| TW201106969A (en) | 2011-03-01 |
| MX2011010955A (es) | 2012-04-02 |
| JP2012524083A (ja) | 2012-10-11 |
| SG175289A1 (en) | 2011-11-28 |
| WO2010123891A1 (en) | 2010-10-28 |
| CN102458467A (zh) | 2012-05-16 |
| KR20120096401A (ko) | 2012-08-30 |
| CR20110553A (es) | 2012-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076344A1 (es) | Metodo de terapia complementaria contra el cancer | |
| PE20080663A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti-her2 | |
| AR054254A1 (es) | Terapia adyuvante con trastuzumab (herceptin registrado) | |
| CO6150193A2 (es) | Terapia tumoral con anticuerpo anti-vegf | |
| JP2017510661A5 (es) | ||
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| JP2013510868A5 (es) | ||
| PH12015501709A1 (en) | Administration of an-activin-a compound to a subject | |
| PE20090681A1 (es) | Prediccion de respuesta a un inhibidor her | |
| EA201490779A1 (ru) | Применение ингибитора димеризации her2 пертузумаба в качестве промышленного изделия и промышленное изделие, включающее ингибитор димеризации her2 пертузумаб | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| RU2012154025A (ru) | Способы лечения | |
| CR10308A (es) | Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| UA114277C2 (uk) | Антиангіогенна терапія для лікування раку яєчника | |
| PE20090245A1 (es) | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos | |
| CL2012000229A1 (es) | Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular. | |
| EP4378482A3 (en) | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| BR112012030318A2 (pt) | composto específicos de anti-cd160 para o tratamento de transtornos oculares com base em neoangiogênese | |
| EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
| PE20160994A1 (es) | Compuestos al receptor-3 del factor de crecimiento del fibroblasto (fgfr3) y metodos de tratamiento | |
| Lindenblatt et al. | Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |